Andrius Žučenka: Congratulations to All the Investigators Involved in the PARADIGM trial
Andrius Žučenka, Assistant professor at Vilniaus universitetas / Vilnius University, shared a post on LinkedIn:
“First and foremost, huge congratulations to all the investigators and everyone involved in the Paradigm trial, the hottest acute myeloid leukemia (AML) topic at the American Society of Hematology 2025. King 7+3 took a massive blow. But has lord HMA+Ven truly won?
Before reading further I sincerely recommend listening to the most recent Wolverheme podcast.
Bernard Marini and Anthony Perissinotti superbly analyzed the presented abstract in such great detail, that there’s no point for me to go through specific trial data here, (KUDOS, guys). I want to simply present my few thoughts from a general/our center’s perspective.”
Read full paper here.
Get the latest updates on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy